Chronic GVHD: Intersecting Aspects in Systemic and Ocular Disease

摘要： 慢性眼部移植物抗宿主病（oGVHD）已被认为是同种异体移植后的重要并发症。 造血干细胞移植（HSCT），是长期发病率和死亡率的主要原因 异基因造血干细胞移植后拟议举行的题为“慢性移植物抗宿主病：系统性 和眼部疾病”将解决干眼和眼表疾病领域中固有的困难 由于慢性眼部GVHD -传播信息和开发新管理的困难 在一个快速变化的学科（眼部GVHD的科学和临床治疗）的战略，其中利益相关者 来自多个不同的群体（临床医生，临床实习生和眼科，血液学， 肿瘤学和免疫学）。这次会议致力于眼科医生和 在慢性GVHD和干眼/眼表疾病领域工作的血液学家/肿瘤学家。通过 汇集了来自不同学科的临床医生和科学家，包括国家认可的专家， 会议将降低沟通障碍，促进跨学科研究和教育， 有助于改善慢性眼部GVHD患者的管理。 我们于2016年10月22日在伊利诺伊大学进行了第二次慢性GVHD会议， 芝加哥（UIC）医学院（COM）学习中心。我们建议今后的会议（2017-2022年）采用示范模式 关于2016年会议的成功形式。本申请的总体目标是要求 支持下一个五年期年度会议的各个方面，以实现三个目标。刺激 临床和翻译跨学科合作和新的研究领域，会议将带来 全国公认的专家（血液学家/肿瘤学家和眼科医生）一起传播新的 在慢性全身和眼部GVHD领域的发现（目的1）。促进机构间和 在研究，临床实践和教育的跨学科机会，会议将汇集五个 骨髓移植计划和六个眼科部门在芝加哥地区讨论 他们对HSCT和慢性GVHD管理方法的差异，以及 临床和研究合作（目标2）。加强初级和高级科学家之间的合作， 血液学/肿瘤学和眼科学领域，将颁发20个旅行奖，以增加 从事研究职业发展和早期基础科学的临床医生的参与 眼表疾病和GVHD领域的研究人员（目标3）。将优先考虑妇女， 少数民族和残疾人。慢性GVHD会议已计划在 根据继续医学认证理事会的基本领域和政策， 教育（ACCME）的赞助下，伊利诺伊大学芝加哥（UIC）。的范围和格式 会议是独特的，非常不同于小型指导课程或共识会议， 眼GVHD在过去3年举行。

Abstract: Chronic ocular GVHD (oGVHD) has been recognized as an important complication after allogeneic hematopoietic stem cell transplantation (HSCT) and is the leading cause of long-term morbidity and mortality following allogeneic HSCT. The proposed meeting entitled “Chronic GVHD: Intersecting aspects in systemic and ocular disease” will address a difficulty that is intrinsic in the area of dry eye and ocular surface disease due to chronic ocular GVHD - the difficulty in disseminating information and developing new management strategies in a fast-changing discipline (science and clinical treatment of ocular GVHD) where the stakeholders come from multiple disparate pools (clinician, clinical trainees and researchers in ophthalmology, hematology, oncology and immunology). This meeting is devoted to the intersection between ophthalmologist and hematologists/oncologists working in the areas of chronic GVHD and dry eye/ocular surface disease. By bringing together clinicians and scientists from different disciplines, including nationally recognized experts, this meeting will lower the communication barrier and promote interdisciplinary research and education and facilitate improvements in the management of patients with chronic ocular GVHD. We conducted the second Chronic GVHD Meeting on October 22, 2016 at the University of Illinois at Chicago (UIC) College of Medicine (COM) learning center. We propose to model future meetings (2017-2022) on the successful format of the 2016 meeting. The overall objective of this grant application is to request support for aspects of the annual meeting for the next 5-year period for achieving three aims. To stimulate clinical and translational interdisciplinary collaborations and new lines of research, the meeting will bring together nationally recognized experts (hematologist/oncologists and ophthalmologists) for disseminating new findings in the area of chronic systemic and ocular GVHD (Aim 1). To stimulate inter-institutional and interdisciplinary opportunities in research, clinical practice and education, the meeting will bring together five bone marrow transplant programs and six ophthalmology departments in the Chicago area to discuss differences in their approach to HSCT and chronic GVHD management and impediments/opportunities in clinical and research collaborations (Aim 2). To increase collaboration amongst junior and senior scientists in the fields of hematology/oncology and ophthalmology, 20 travel awards will be made to increase the participation of clinicians who are pursuing research career development and early stage basic science researchers in the areas of ocular surface disease and GVHD (Aim 3). Preference will be given to women, racial/ethnic minorities and persons with disabilities. The Chronic GVHD meeting has been planned in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) under the sponsorship of University of Illinois at Chicago (UIC). The scope and format of the meeting is unique and very different from the small instruction courses or consensus meetings on chronic ocular GVHD held in the past 3 years.